Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16667373 | 1.00 | TP53 (0.38) | TP53OR51E2DPP4SLC1A2SLC1A3 | |
| SCHEMBL1406004 | 1.00 | TP53 (0.38) | TP53OR51E2DPP4SLC1A2SLC1A3 | |
| SCHEMBL1406003 | 1.00 | TP53 (0.38) | TP53OR51E2DPP4SLC1A2SLC1A3 | |
| SCHEMBL16667376 | 1.00 | TP53 (0.38) | TP53OR51E2DPP4SLC1A2SLC1A3 | |
| SCHEMBL6234993 | 0.78 | TP53 (0.35) | TP53OR51E2DPP4 | |
| SCHEMBL2437498 | 0.75 | — | — | |
| SCHEMBL6239351 | 0.75 | CHRM1 (0.40) | SLC1A2SLC1A3SLC1A1TSHR | |
| SCHEMBL395419 | 0.74 | TDP1 (0.33) | OR51E2 | |
| SCHEMBL392365 | 0.74 | TDP1 (0.33) | OR51E2 | |
| SCHEMBL197703 | 0.74 | TDP1 (0.33) | OR51E2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828594-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160355801-A1 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | VERENIUM CORPORATION | 2016-12-08 | — | — | US | disclosed |
| US-9217164-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2015-12-22 | — | — | US | disclosed |
| EP-2327766-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-12-02 | — | — | EP | disclosed |
| EP-2319919-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-1576108-B1 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | BASF ENZYMES LLC (US) | 2015-07-08 | — | — | EP | disclosed |
| EP-2327767-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-2327765-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-04-01 | — | — | EP | disclosed |
| US-8906663-B2 | Nitrilases | VERENIUM CORPORATION (US) | 2014-12-09 | — | — | US | disclosed |
| US-8778651-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | VERENIUM CORPORATION (US) | 2014-07-15 | — | — | US | disclosed |
| US-20100086986-A1 | Increased activity and stability at increased pH and temperature; making a chiral alpha -hydroxy acid molecule, a chiral amino acid molecule, a chiral beta -hydroxy acid molecule, or a chiral gamma-hydroxy acid molecule, from a molecule with a cyanohydrin moiety or an aminonitrile moiety | VERENIUM CORPORATION (US) | 2010-04-08 | — | — | US | disclosed |
| US-7651849-B2 | Increased activity and stability at increased pH and temperature | VERENIUM CORPORATION | 2010-01-26 | — | — | US | disclosed |
| US-20100009426-A1 | synthetic or recombinant polypeptide having a nitrilase activity; have increased activity and stability at increased pH and temperature | VERENIUM CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
| US-7608445-B1 | Nitrilases, nucleic acids encoding them and methods for making and using them | VERENIUM CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| US-20090176976-A1 | Increased activity and stability at increased pH and temperature | VERENIUM CORPORATION | 2009-07-09 | — | — | US | disclosed |
| US-7521216-B2 | Nitrilases and methods for making and using them | VERENIUM CORPORATION (US) | 2009-04-21 | — | — | US | disclosed |
| EP-2039762-A2 | Nitralases | Verenium Corporation (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20040014195-A1 | Nitrilases, nucleic acids encoding them and methods for making and using them | DIVERSA CORPORATION (US) | 2004-01-22 | — | — | US | disclosed |
| US-20040002147-A1 | Nitrilases | DIVERSA CORPORATION | 2004-01-01 | — | — | US | disclosed |
| US-20030124698-A1 | Which stereoselectively hydrolyze nitrites or cyanohydrins into acids and ammonia | DIVERSA CORPORATION | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014195-A1 | Nitrilases, nucleic acids encoding them and methods for making and using them | RNGTT, NSUN2, NSUN3 | TP53 1317/4885OR51E2 2443/4885DPP4 2633/4885 |
| US-20040002147-A1 | Nitrilases | RNGTT, DNTT, NOP2 | TP53 978/4885OR51E2 2786/4885DPP4 1969/4885 |
| US-20030124698-A1 | Which stereoselectively hydrolyze nitrites or cyanohydrins into acids and ammonia | NIT2, DNPH1, ASNS | TP53 2212/4885OR51E2 1461/4885DPP4 2034/4885 |
| US-20100086986-A1 | Increased activity and stability at increased pH and temperature; making a chiral alpha -hydroxy acid molecule, a chiral amino acid molecule, a chiral beta -hydroxy acid molecule, or a chiral gamma-hydroxy acid molecule, from a molecule with a cyanohydrin moiety or an aminonitrile moiety | ASPH, AHSA1, DNPH1 | TP53 507/4885OR51E2 1539/4885DPP4 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.